Sex hormones shape cardiovascular risk in subtle yet powerful ways. From estrogen-driven changes in coagulation to formulation-specific differences in VTE risk, the nuance matters. Transdermal estradiol offers a safer path, while ethinyl estradiol reminds us that dose and route are destiny. The key is not avoidance—but precision: matching therapy to individual risk.

Three takeaways: • Formulation matters • First year matters • Patient factors matter

#Cardiology #Thrombosis #PrecisionMedicine #HormoneTherapy